Clinical significance of half-hepatic blood flow occlusion technology in patients with hepatocellular carcinoma with cirrhosis

Table 1 Comparison of baseline data between the two groups of patients, n (%)

Normal information	Research group (n = 44)	Control group (n = 44)	t/χ2 value	P value
Age (yr)	60.6 ± 5.0	61.3 ± 5.5	-0.625	0.534
Lesion diameter (cm)	5.18 ± 1.00	5.08 ± 1.30	0.404	0.687
Serum AFP (ng/L)	240.8 ± 75.6	228.6 ± 66.3	0.805	0.423
Sex			0.733	0.392
Male	26 (59.09)	22 (50.00)
Female	18 (40.91)	22 (50.00)
Child-Pugh stage			1.252	0.263
A stage	40 (100)	37 (84.09)
B stage	4 (9.09)	7 (15.91)
Hepatitis B virus infection			1.286	0.257
Yes	32 (72.73)	27 (61.36)
No	12 (27.27)	17 (38.64)
Surgical resection range			0.786	0.375
≥ 3 liver segments	18 (40.91)	14 (31.82)
< 3 liver segments	26 (59.09)	30 (68.18)